Status:
COMPLETED
A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy
Lead Sponsor:
Pfizer
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
20-64 years
Phase:
PHASE1
Brief Summary
Study B1621018 will assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Dose Levels of Pf-04937319 in Japanese Subjects with Type 2 Diabetes Mellitus As Monotherapy
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes, on diet/exercise therapy only or background therapy with 1 oral anti-diabetic agent (excluding Actos)
Exclusion
- Patients with cardiovascular event
- Patients with diabetic complications
- Female subjects who are pregnant or planning to become pregnant
- Subjects with unstable medical conditions (eg, hypertension)
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT02292433
Start Date
January 1 2015
End Date
March 1 2015
Last Update
March 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
P-one Clinic, Keikokai Medical Corporation
Hachioji-shi, Tokyo, Japan, 192-0071